InMed Pharmaceuticals Inc
For the period ended Sep 30, 2024. Filed Nov 14, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2024 · Filed Nov 14, 2024
INM$15.56+17.8%Stored close · as of Nov 6, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS UNAUDITED
For the Three Months ended September 30, 2024 and 2023
| For the Three Months Ended | ||||
|---|---|---|---|---|
| September 30, | ||||
| 2024 · 2023 | ||||
| $ · $ | ||||
| Cash provided by (used in): | ||||
| Operating Activities | ||||
| Net loss | (1,677,868) | (2,536,828) | ||
| Items not requiring cash: | ||||
| Amortization and depreciation | 54,579 | 54,832 | ||
| Share-based compensation | 28,964 | 25,191 | ||
| Amortization of ROU assets | 90,401 | 94,532 | ||
| Interest income received on short-term investments | (519) | (538) | ||
| Unrealized foreign exchange loss | 5,270 | 2,018 | ||
| Inventory write-down | - | 92,930 | ||
| Changes in operating assets and liabilities: | ||||
| Inventories | 24,251 | 390,329 | ||
| Prepaids and other currents assets | 328,867 | 283,018 | ||
| Other non-current assets | - | 3,118 | ||
| Accounts receivable | 68,143 | 94,549 | ||
| Accounts payable and accrued liabilities | (642,392) | (562,484) | ||
| Deferred rent | - | (16,171) | ||
| Lease obligations | (106,506) | (98,709) | ||
| Total cash used in operating activities | (1,826,810) | (2,174,213) | ||
| Investing Activities | ||||
| Sale of short-term investments | 21,324 | 21,317 | ||
| Purchase of short-term investments | (21,324) | (21,317) | ||
| Total cash used in investing activities | - | - | ||
| Financing Activities | ||||
| Proceeds from the private placement | 1,030,063 | - | ||
| Private placement issuance costs | (191,824) | - | ||
| Total cash provided by financing activities | 838,239 | - | ||
| Decrease in cash during the period | (988,571) | (2,174,213) | ||
| Cash and cash equivalents beginning of the period | 6,571,610 | 8,912,517 | ||
| Cash and cash equivalents end of the period | 5,583,039 | 6,738,304 | ||
| SUPPLEMENTARY CASH FLOW INFORMATION: | ||||
| Cash Paid During the Period for: | ||||
| Income Taxes | $ | - | $ | - |
| Interest | $ | - | $ | - |
| SUPPLEMENTARY DISCLOSURE OF NON-CASH INVESTING AND FINANCING ACTIVITIES: | ||||
| Recognition of ROU asset and corresponding operating lease liability | $187,223 | $ | - | |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.